Composition, efficacy, and safety comparisons
| . | Axicabtagene ciloleucel . | Tisagenlecleucel . | Lisocabtagene maraleucel . |
|---|---|---|---|
| Study populations | DLBCL, TFL, PMBCL | R/R DLBCL | CORE DL2* |
| Target antigen | CD19 | CD19 | CD19 |
| Lymphodepletion | Flu/Cy | Flu/Cy | Flu/Cy |
| Costimulatory domain | CD28 | 4-1BB | 4-1BB |
| T-cell composition | Unspecified | Unspecified | 1:1 CD4:CD8 |
| Cell dose | 2 × 106 cells/kg | 5 × 108 | 1 × 108 |
| OR (best) | 82% (N = 108) | 53% (N = 81) | 81% (N = 27) |
| OR (6 mo) | 41% (N = 101) | 37% (N = 46) | 50% (N = 14) |
| CR (best) | 58% (N = 108) | 40% (N = 81) | 63% (N = 27) |
| CR (6 mo) | 36% (N = 101) | 30% (N = 46) | 50% (N = 14) |
| Any grade CRS/NT† | 94%/87% (N = 108) | 58%/21% (N = 99) | 24%/17% (N = 29) |
| ≥Grade 3 CRS† | 12% (N = 108) | 23% (N = 99) | 0% (N = 29) |
| ≥Grade 3 NT† | 31% (N = 108) | 12% (N = 99) | 7% (N = 29) |
| Grade 5 AEs | 4% (N = 108)‡ | None | — |
| . | Axicabtagene ciloleucel . | Tisagenlecleucel . | Lisocabtagene maraleucel . |
|---|---|---|---|
| Study populations | DLBCL, TFL, PMBCL | R/R DLBCL | CORE DL2* |
| Target antigen | CD19 | CD19 | CD19 |
| Lymphodepletion | Flu/Cy | Flu/Cy | Flu/Cy |
| Costimulatory domain | CD28 | 4-1BB | 4-1BB |
| T-cell composition | Unspecified | Unspecified | 1:1 CD4:CD8 |
| Cell dose | 2 × 106 cells/kg | 5 × 108 | 1 × 108 |
| OR (best) | 82% (N = 108) | 53% (N = 81) | 81% (N = 27) |
| OR (6 mo) | 41% (N = 101) | 37% (N = 46) | 50% (N = 14) |
| CR (best) | 58% (N = 108) | 40% (N = 81) | 63% (N = 27) |
| CR (6 mo) | 36% (N = 101) | 30% (N = 46) | 50% (N = 14) |
| Any grade CRS/NT† | 94%/87% (N = 108) | 58%/21% (N = 99) | 24%/17% (N = 29) |
| ≥Grade 3 CRS† | 12% (N = 108) | 23% (N = 99) | 0% (N = 29) |
| ≥Grade 3 NT† | 31% (N = 108) | 12% (N = 99) | 7% (N = 29) |
| Grade 5 AEs | 4% (N = 108)‡ | None | — |
Courtesy of and adapted from C. Turtle.
AE, adverse event; Cy, cyclophosphamide; DL2, dose level 2; Flu, fludarabine; OR, overall response.
CORE group (proposed pivotal population) including DLBCL, not otherwise specified TFL, FL3B, ECOG 0-1, and R/R patients.
CAR T toxicity grading scales differ across studies.
2 patients grade 5 CRS.